API Holdings (Pharmeasy) Unlisted Shares
PharmEasy FY24 results: Revenue falls nearly 15%, losses narrow by 51%
Fina
2 min read
PharmEasy Narrow Losses Despite Revenue Drop.
Expert Analysis
Revenue Decline: PharmEasy’s consolidated revenue from operations declined by 14.7% to ₹5,664 crore in FY24 from ₹6,643 crore in FY23.
Drop in Total Income: Total income fell to ₹5,758 crore in FY24 from ₹6,699 crore in FY23.
Loss Reduction: PharmEasy’s losses narrowed by 51% to ₹2,533 crore in FY24 from ₹5,211 crore in FY23, aided by a 79% reduction in goodwill impairment charges to ₹582 crore from ₹2,825 crore in FY23.
Expense Reduction: Expenses dropped 19% from Rs 8,974 to ₹7,254 crores, with stock-in-trade costs reducing to ₹4,572 crores in FY24 from ₹5,512 crore in FY23 and employee expenses to ₹699 crores from ₹1,283 crores.
Increase in Finance Costs: Finance costs increased from Rs 665 crore in FY23 to ₹728 crore in FY24.
Valuation Markdown: API Holdings, valued at $5.6 billion in 2021, saw a 92% markdown to $458 million, as per SEC filings.
Funding at Reduced Valuation: In April 2024, API Holdings experienced a 90% haircut in its valuation after securing $216 million in funding from Manipal Education and Medical Group (MEMG) and existing investors.
PharmEasy cut losses and expenses but faces valuation challenges, competition, and finance cost increases alongside revenue and income declines.
Precize Daily Pulse
The latest news in the world of Unlisted Shares, summarised by our experts.
Company
Our Office
Office No. 1219, The Summit Business Park, Andheri Kurla Road, Andheri East, Mumbai, Maharashtra - 400093
Find us on Googlesupport@precize.in
+91 7738336457
All trademarks and logos or registered trademarks and logos found on this Site or mentioned herein belong to their respective owners and are solely used for informational and educational purposes.
The material presented in this advertisement is for informational purposes only and should not be construed as investment advice or investment availability. It is not a recommendation of, or an offer to sell or solicitation of an offer to buy, any particular unlisted share, security, strategy, or investment product. Investing in the private market and securities involves risks, including the potential loss of money, and past performance does not guarantee future results. Market trends, data interpretations, graph projections are provided for informational and illustrative purposes and may not reflect actual future performance. Nothing on this website should be construed as personalized investment advice or should not be treated as legal, financial, or any other form of advice. Precize is not liable for financial or any other form of loss incurred by the user or any affiliated party based on information provided herein.
Precize is neither a stock exchange nor does it intend to get recognized as a stock exchange under the Securities Contracts Regulation Act, 1956. Precize is not authorized by the capital markets regulator to solicit investments. The securities traded on these platforms are not traded on any regulated exchange.
The website will be updated regularly.
Copyright © 2026 - Precize - All Rights Reserved